Stryker Enters China Race With Trauson Bid
This article was originally published in The Gray Sheet
Executive Summary
The acquisition of Trauson would give Stryker deep roots into the untapped territories of China’s $1.5 billion orthopedics industry, the so-called second- and third-tier markets in lesser developed areas where multinationals haven’t been able to access.